Atlas Capital Advisors Inc. Takes $43,000 Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Atlas Capital Advisors Inc. bought a new position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 5,000 shares of the biopharmaceutical company’s stock, valued at approximately $43,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Charles Schwab Investment Management Inc. boosted its holdings in shares of Ocular Therapeutix by 146.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,110,460 shares of the biopharmaceutical company’s stock worth $9,661,000 after acquiring an additional 660,080 shares during the period. The Manufacturers Life Insurance Company boosted its stake in Ocular Therapeutix by 11.3% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 130,202 shares of the biopharmaceutical company’s stock valued at $1,133,000 after purchasing an additional 13,238 shares during the period. FMR LLC increased its position in Ocular Therapeutix by 7,098.7% during the 3rd quarter. FMR LLC now owns 434,369 shares of the biopharmaceutical company’s stock worth $3,779,000 after buying an additional 428,335 shares during the period. Verition Fund Management LLC bought a new position in Ocular Therapeutix during the 3rd quarter worth $544,000. Finally, Wellington Management Group LLP lifted its holdings in shares of Ocular Therapeutix by 47.1% during the third quarter. Wellington Management Group LLP now owns 462,864 shares of the biopharmaceutical company’s stock worth $4,027,000 after buying an additional 148,310 shares in the last quarter. Institutional investors and hedge funds own 59.21% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on the stock. JMP Securities set a $19.00 price target on shares of Ocular Therapeutix in a research report on Tuesday, March 4th. HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price on shares of Ocular Therapeutix in a report on Tuesday, March 4th. Royal Bank of Canada started coverage on Ocular Therapeutix in a research note on Tuesday, March 18th. They issued an “outperform” rating and a $17.00 price target for the company. Finally, Needham & Company LLC initiated coverage on Ocular Therapeutix in a research note on Tuesday, March 11th. They set a “buy” rating and a $15.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $16.38.

Insider Buying and Selling

In other news, insider Donald Notman sold 11,119 shares of the company’s stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $7.81, for a total transaction of $86,839.39. Following the completion of the transaction, the insider now directly owns 193,444 shares in the company, valued at approximately $1,510,797.64. This represents a 5.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Pravin Dugel sold 21,475 shares of the firm’s stock in a transaction on Monday, February 24th. The shares were sold at an average price of $6.87, for a total value of $147,533.25. Following the sale, the insider now directly owns 3,520,318 shares in the company, valued at approximately $24,184,584.66. This trade represents a 0.61 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 38,895 shares of company stock worth $283,772 in the last three months. 3.50% of the stock is owned by corporate insiders.

Ocular Therapeutix Trading Down 9.1 %

Shares of OCUL stock opened at $6.36 on Friday. Ocular Therapeutix, Inc. has a fifty-two week low of $4.06 and a fifty-two week high of $11.78. The stock’s fifty day moving average price is $7.42 and its two-hundred day moving average price is $8.69. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.94 and a current ratio of 13.01. The company has a market cap of $1.01 billion, a PE ratio of -4.82 and a beta of 1.49.

Ocular Therapeutix (NASDAQ:OCUL) last released its earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.05). The business had revenue of $17.08 million during the quarter, compared to the consensus estimate of $16.89 million. Ocular Therapeutix had a negative net margin of 283.74% and a negative return on equity of 45.18%. Equities analysts predict that Ocular Therapeutix, Inc. will post -0.98 EPS for the current fiscal year.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.